6 hours a week on calls? Help me understand that. I can see a district call every now and then but tell me what the other calls are....
-
Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page
BMS attributes Sotyktu failure to access, but it's really SAFETY
- Thread starter anonymous
- Start date
-
- Tags
- None
6 hours a week on calls? Help me understand that. I can see a district call every now and then but tell me what the other calls are....
Standing District Call. Training Call. Call for meeting preparation. Medical Call. Regional Call. DEI call. Cross functional (run by market access) call. Plus ad hoc calls that come up because people snap when the numbers come out.
Its many things. Including the fact our reps aren't great and to focused on "selling" in the traditional pharma way.
Speaking of failure….imagine not even remembering being VP, but still “running” for Prez- it’s unbelievable. November 2024!
BIYOTCH please. You are not having that many calls. You have maybe a district call a week. Medical isn't calling unless a change has been made to label or new data posted. Training isn't calling because you aren't close to POA and there hasn't been DEI calls since COVID.
I know who you are calling though...your dentist, dry cleaner, your proctologist, and your mama!!!!
Seriously come back when you actually do something AMGEN REP!
oh please no
Novartis and galderma folks tanked this launch and dug a hole so deep we won’t dig out of it
and we all know it
who thought it was a bright idea to bring these people over with stale tactics
too late to dump all of them out and save us
what a shame for such a good drug
please enligthen us as to what these stale tactics were...Thx Karen 
please enligthen us as to what these stale tactics were...Thx Karen
Seriously? The Novartis folks bungled this launch in every way, and it was not out of laziness, and bringing over so many of them who did not work hard over at Novartis. Their experience was with an already established drug with great access, not with launching a new drug. They had no clue how to grow this drug. Combination of poor strategy and poor work ethic was fatal.
Thanks Karen- you still have have not provided any specific actions taken by these managers that destroyed the launch-what strategies did not work? how does a manager being lazy have anything to do with market share? Managers provide no value to sales at all-they check boxes and write coaching reports-thats it
Yes, you're right, David, you could eliminate all middle managers, save millions, and not lose sales
Cosentyx has no access, Talz has the access...just sayin
It doesn’t now but it did.
Cosentyx used to have preferred access all around, but they lost it. The best access now is Skyrizi, follow by O-Shitzla, then Lilly and JNJ. We suck.Cosentyx has no access, Talz has the access...just sayin
Exactly and we brought over folks from Novartis with no clue or work ethic to successfully launch a new drug with poor access
Monica was weak and in over her head
But little she could do with Novartis Galderma folks between her and the street and gumming up the works
problems way way deeper than just Monica
Karen can you please explaing how a manager working "harder" affects sales? Still have not provided any specific tactics/strategies these managers deployed that failed...fact is you signed up to sell a dog product and now you are pointing fingers for your lack of sales-make better career choices
Here’s how this was supposed to work:
1. Everyone knew access would be bad at launch for a new drug in this category. You were told this at the launch meeting.
2. To gain access, BMS needed to prove there was demand in the market for it, so that payers would give up existing, lucrative rebates from other drugs in favor of Sotyktu financial incentives.
3. It was reps’ job to generate demand based on clinical superiority to Otezla AND the guarantee of free drug while the access situation was poor. Cozy relationships with Derms were supposed to help with the sale because non-Derm reps can’t even get in the door.
Bottom line: if there’s no demand, then access won’t happen. Those are just the facts of this market.
So what would you brainiacs have done differently?
1. Everyone knew access would be bad at launch for a new drug in this category. You were told this at the launch meeting.
2. To gain access, BMS needed to prove there was demand in the market for it, so that payers would give up existing, lucrative rebates from other drugs in favor of Sotyktu financial incentives.
3. It was reps’ job to generate demand based on clinical superiority to Otezla AND the guarantee of free drug while the access situation was poor. Cozy relationships with Derms were supposed to help with the sale because non-Derm reps can’t even get in the door.
Bottom line: if there’s no demand, then access won’t happen. Those are just the facts of this market.
So what would you brainiacs have done differently?